SYRE Q4 2021 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M

Gross Profit

$3M86.2% margin

Operating Income

-$20M-561.0% margin

Net Income

-$20M-561.1% margin

EPS (Diluted)

$-10.36

QoQ Revenue Growth

+160.5%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$110M

Total Liabilities

$26M

Stockholders' Equity

$84M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$0	—
Gross Profit	$3M	$0	—
Operating Income	-$20M	-$23M	+10.2%
Net Income	-$20M	-$23M	+10.0%